Researchers from Roswell Park Cancer Institute, Krankenhaus Nordwest and two other institutions have published results of parallel phase II studies testing a promising immunotherapy regimen in patients with melanoma and ovarian cancer
A report from the Center for International Blood and Marrow Transplant Research shows that outcomes for transplant patients treated at Roswell Park Cancer Institute were superior, positioning RPCI among the top 9% of U.S. centers performing the procedure.
RPCI surgeon receives $100,000 CHEST Foundation grant to develop diagnostic blood test for detection of lung cancer.
Prestigious quality designations from employer coalition, oncology association are latest commendations of RPCI from national organizations.
Ravindra K. Pandey, PhD, of the Department of Cellular Stress Biology at Roswell Park Cancer Institute received the Jacob F. Schoellkopf Medal from a chapter of the American Chemical Society for his field-leading work in photodynamic therapy.
RPCI's Andrew Hyland, PhD, is lead investigator on a study funded by the NIH's National Institute on Drug Abuse that will be the largest study to date of tobacco use in the U.S.
Researchers from Roswell Park Cancer Institute, Boston University and the University of North Carolina are collaborating on the largest study to date on breast cancer in African-Americans.
Dr. Nestor Rigual has been appointed Medical Director of the Photodynamic Therapy Center at Roswell Park Cancer Institute. PDT was developed at RPCI, which is a worldwide leader in its use as a cancer therapy.
Paper in Science Translational Medicine by Dr. Katerina Gurova and colleagues is the first published research on anticancer drugs called curaxins, and outlines the mechanism by which they inhibit tumor cell growth and division.
National dietary study now open for accrual at Roswell Park Cancer Institute. The multisite trial will assign men with small, low-grade prostate tumors to an intervention designed to encourage a diet low in animal products.
Joseph Lau and three Roswell Park Cancer Institute colleagues will share in a $17.6 million award from the NIH's National Heart, Lung, and Blood Institute. They'll explore the role of sugars in production of blood cells, toward the goal of developing new therapies.
Roswell Park Cancer Institute has met National Cancer Institute qualifications for the CQIE program, designed to guide imaging practices related to early detection of cancer tumors.
Among the studies Roswell Park Cancer Institute physicians were invited to present at ASCO 2011 are an investigation into an experimental regimen for solid tumors and final results of a phase I trial of a promising regimen for pancreatic cancer.
In three papers published in the American Journal of Preventive Medicine, Roswell Park Cancer Institute researchers report their conclusions from a comprehensive evaluation of cigarette package labeling.
HoST system modules are the first training applications for specific robot-assisted procedures; available for robot-assisted prostatectomy, hysterectomy, cystectomy and complex extended lymph-node dissection.
Six of the best-known and most-respected pioneers from the urology field will reveal how and when “aha!” moments of discovery changed to historical milestones May 16 at a seminar hosted by Roswell Park Cancer Institute in Washington, DC.
Philip McCarthy, Jr., MD, of Roswell Park Cancer Institute presented data from a CALGB trial at the International Myeloma Workshop. Patients receiving maintenance lenalidomide therapy had higher survival rate and lower risk of disease progression.
Traveling to Nigeria at the request of the Nigerian Urologic Society and IVUmed, Willie Underwood III, MD, MPH, MSci, of Roswell Park Cancer Institute recently performed that country’s first documented radical prostatectomy.
Roswell Park Cancer Institute has released Quality 2011, the Institute's first significant compilation of outcomes and quality data to appear in print.
Roswell Park Cancer Institute (RPCI) has been named a Blue Distinction Center for Transplants — a national designation awarded to centers that demonstrate high quality of care and patient outcomes for bone marrow/stem cell transplant procedures — by BlueCross BlueShield of Western New York.
Roswell Park Cancer Institute (RPCI) is one of 27 institutions selected to be part of the Cancer Immunotherapy Trials Network (CITN), a new NCI-funded initiative to conduct research on immunologic agents, toward the goal of making them available to patients as cancer treatments.
Provenge, the nation’s first FDA-approved cancer treatment vaccine, is now available at Roswell Park Cancer Institute (RPCI). RPCI is the first institution in Western New York to offer this vaccine, which is a treatment for advanced prostate cancer available to men who meet eligibility requirements.
Roswell Park Cancer Institute (RPCI) in Buffalo, NY has become the first institution to be accredited as a Training Institute in Robot-Assisted Surgery by the Société Internationale d’Urologie (SIU), and will host three-month Robot-Assisted Mini-Fellowships to promising physicians early in their careers.
New spinoff company forms out of research done at Roswell Park Cancer Institute; Buffalo-based company will develop photosensitizing compounds used in photodynamic therapy.
Roswell Park Cancer Institute has earned Leapfrog Top Hospital status for the first time. Awarded annually by a coalition of public and private employers, this designation is based on survey responses from approximately 1,200 institutions. RPCI is one of 65 U.S. hospitals included on this year's list.
Dr. Philip McCarthy Jr. presents updated data from a National Cancer Institute/Cancer and Leukemia Group B study on maintenance treatment with lenalidomide following stem cell transplant for patients with newly diagnosed multiple myeloma. In the Phase III, randomized double-blind study, more than twice as many of those in the placebo arm saw their disease progress, compared to those who were treated.
It is hoped results of this study will open new areas for investigation regarding the basic biology of the relationship between immune factors and aggressive breast cancer.
Understanding the cytokine, or IL-6 requirements, for lymphocyte recruitment during acute inflammation may lead to novel intervention strategies in chronic inflammatory disorders and cancer vaccines.
Research may help to explain the variations that lead to Vitamin D3 deficiency, and could predict the efficacy of Vitamin D3-based interventions, and those at higher risk for developing cancer.
To see if CellSearch could predict patient response to therapy earlier than traditional measures. Patients could be spared the expense and unpleasant side effects of continuing with an ineffective treatment course.
A collaboration between the Center for Robotic Surgery at Roswell Park Cancer Institute (RPCI) and the University at Buffalo (UB)’s School of Engineering and Applied Sciences has produced one of the world’s first simulators that closely approximates the “touch and feel” of the da Vinci TM robotic surgical system.
Neal Wilkinson, MD, has joined Roswell Park Cancer Institute (RPCI) as a physician and Associate Professor of Surgery in the Surgical Oncology department.
Dr. Donald L. Trump, President and CEO of Roswell Park Cancer Institute (RPCI), America’s first cancer center, will have his head shaved by a Roswell Park cancer patient on March 3, 2010 to honor the Institute’s 26,292 patients, and to encourage others to participate in the “Goin’ Bald for Bucks” program.
Roswell Park Cancer Institute (RPCI) announced the appointment of Irwin Gelman, PhD, as Chair, Department of Genetics. Dr. Gelman has been with RPCI since 2003. His research focuses on therapies to target prostate cancer, and his work has appeared in more than 50 journals and periodicals.
Some of the nation’s rising music stars have joined Roswell Park Cancer Institute (RPCI), the nation’s first cancer center, in an effort to show young people that they can help build a world without cancer.
Roswell Park Cancer Institute (RPCI) announced a grant award for $1.7M from the National Institute for Allergies and Infectious Disease to study some human therapeutics targeting acute radiation syndrome. Andrei Gudkov, PhD, Senior Vice President Basic Science; Chair, Cell Stress Biology; of RPCI’s Scientific Affairs department, is the principal investigator.
Christine Ambrosone, PhD, Chair of Cancer Prevention and Control and Kelvin Lee, MD, Chair of Immunology at Roswell Park Cancer Institute (RPCI), have received a grant for $165,000 from the Breast Cancer Research Foundation to study the possible link between adaptation to endemic infectious disease and the possibility of being diagnosed with aggressive breast cancers among women of African ancestry.
The Technology Transfer Office of Roswell Park Cancer Institute (RPCI) announced it has signed a licensing agreement with Zhejiang Hisun Pharmaceutical Co. Ltd., for tumor imaging technology developed by RPCI researcher Ravindra Pandey, PhD. Zhejiang Hisun Pharmaceutical is one of China’s largest producers of oncology drugs.
Roswell Park Cancer Institute (RPCI) is the recipient of a grant from Susan G. Komen for the Cure for $186,000 to support research exploring the role of certain genetic markers in the development of breast cancer.
Some of the nation’s rising music stars have joined the nation’s first cancer center in an effort to show young people that they can help build a world without cancer. Roswell Park Cancer Institute created a new hip hop song and video called “How Big Is Your Heart.” The MTV-like commercial features cancer patients and nurses dancing alongside professional dancers through the halls and lobby of the cancer hospital.
Trusted health care sources and continuity of care may help reduce the risk of prostate cancer deaths in African-American men, according to a study published in the current issue of the journal Cancer. James Mohler, MD, Chair of the Department of Urology at Roswell Park Cancer Institute (RPCI), and William R. Carpenter, PhD, Department of Health Policy and Management at the University of North Carolina, are lead investigators.
Researchers at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, are strongly advocating a national discussion about the need to vaccinate both young men and women against HPV 16 to prevent head & neck cancers. The call comes amid growing evidence that certain cancers of the head and neck are strongly linked to HPV 16, a specific strain of the human papillomavirus (HPV) that is one of the most common sexually transmitted diseases in the United States. It is estimated that approximately 70% of Americans, both men and women, will be infected with HPV at some point in their lives.
Donald L. Trump, MD, FACP, President & CEO of Roswell Park Cancer Institute (RPCI), has been elected to membership in the Johns Hopkins Society of Scholars. He was inducted into the Society on Wednesday, May 20, and recognized during commencement exercises on May 21 in Baltimore, MD.
William Cance, MD, Chair of Surgical Oncology, Roswell Park Cancer Institute (RPCI) presented "A Small-Molecule Inhibitor, Targeting FAK and Mdm-2 Interaction, Blocks Breast and Colon Tumorigenesis in vivo" at the American Association Cancer Research (AACR) 100th Annual Meeting, 2009.
Nationally recognized medical oncologist Roberto Pili, MD, has been appointed Professor of Oncology, Chief of the Genitourinary Section and Co-Leader of the Genitourinary Program at Roswell Park Cancer Institute (RPCI). Dr. Pili comes to RPCI from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, where he served as Associate Professor of Oncology and Urology.
William G. Cance, MD, has been appointed Chair of the Department of Surgical Oncology and Surgeon-In-Chief at Roswell Park Cancer Institute (RPCI).
Roswell Park Cancer Institute (RPCI) faculty members recently met with the Hungarian Health Minister and other government officials to discuss strategies to reduce smoking in Hungary.
A plant-based diet high in cancer-fighting lignans may be associated with improved survival among postmenopausal women with breast cancer, according to a study presented by Susan E. McCann, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute (RPCI), at the 2008 annual meeting of the American Association for Cancer Research (AACR), April 12-16, in San Diego, CA.
Cellular interactions enable multiple myeloma (MM) cells to survive, proliferate and render chemotherapy ineffective. Kelvin P. Lee, MD, The Jacobs Family Chair in Immunology, Roswell Park Cancer Institute (RPCI), will describe these interactions and outline molecular targets that improve the activity of chemotherapy, at the 2008 annual meeting of the AACR, April 12-16, in San Diego, CA.
Low-molecular-weight heparins block the formation of new blood vessels and prevent tumor growth, according to the results of a study presented by Michael Wong, MD, PhD, FRCPC, Department of Medicine, Roswell Park Cancer Institute (RPCI), at the 2008 annual meeting of the American Association for Cancer Research, April 12-16, in San Diego, CA.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right